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The quantitative results obtained from
the occipital hair were not consistent with
those of the vertex hair (Supplementary
Table S2 and S3 online). The occipital
T levels were not significantly different
between the Korean groups, a finding that
is not concordant with that of an earlier
report obtained from vertex hair (Choi
et al., 2001). In addition, the DHT/T
ratio, one of the indicators of MPB (Choi
et al., 2001; Bang et al., 2004), was lower
in the vertex hair after treatment with 5a-
reductase inhibitors, both finasteride and
dutasteride, but not in the occipital hair
(Ryu et al., 2006; Jung et al., 2011). All
vertex steroid levels except for 11b-OH-
An tended to be slightly lower than
occipital steroid levels in individual
hairs. No significant differences between
two sites were found in any case. This
finding suggests that the distribution of
androgens differs for each region of the
scalp and may be useful for intersite
comparison (Rushton et al., 1991).
The differences in the metabolic ratio of
DHT to T obtained from the vertex hair
shafts were not statistically significant in
any of the groups (Supplementary Table
S1 online). An alternative metabolic ratio
responsible for 5a-reductase activity with
A-dione and T was therefore introduced
because A-dione and T are reversibly
catalyzed by 17b-HSD in the androgen
metabolic process. Although these meta-
bolic ratios tended to increase in both
Caucasian groups, the differences were
not statistically significant (Supplemen-
tary Table S1 online). In contrast to the
5a-reductase activity, the activity of 3b-
HSD, which is indicated by the A-dione
to DHEA metabolic ratio, was higher in
the Korean groups. At the target cell
levels, different androgenic productions
could be regulated by the balance
between 5a-reductase, 3b-HSD, and
17b-HSD (Eicheler et al., 1998).
Although our findings are based on
the epithelial environments and not on
the papilla cells, it confirms the exis-
tence of racial differences in hair steroid
levels, and the results highlight the
necessity for careful monitoring and
controlling for multiple factors along
with race before making a conclusion
with result from the biological fluids.
Further studies would need to compare
the drug efficacies in the balding groups
to provide a personalized and evidence-
based approach to patient treatment.
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TO THE EDITOR
Nevus sebaceus is a common congeni-
tal skin hamartoma, classically appea-
ring as a yellow-hued plaque on the
scalp, face, or neck. It is the hallmark
lesion of Schimmelpenning/nevus seba-
ceus syndrome (OMIM: 163200), a
multisystem disorder that includes a
spectrum of central nervous system,
ocular, skeletal, and cardiovascular
defects. Secondary neoplasms arise within
nevus sebaceus at a modest but elevated
rate (Moody et al., 2012), prompting
disagreement about whether they
should be routinely excised (Shwayder,
2011). Determining the pathogenesis
of nevus sebaceus would provide a
framework to better understand this
lesion and its associated syndrome.
The appearance of nevus sebaceus
along Blaschko’s lines suggests that a
See related commentary on pg 597
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mosaic genetic mutation causes the
lesion, with more extensive multisystem
involvement potentially underlying the
syndromic form (Happle, 1993). Here,
we report a case of an individual with
nevus sebaceus syndrome. As indivi-
duals with this syndrome are uncom-
mon, we sought to identify associated
mutations by comparing the exome
sequence of the nevus sebaceus from
our patient with those of sporadic nevus
sebaceus.
Our index patient is a 38-year-old
woman who was born with Chiari
malformation, myelomeningocele, and
resultant paraplegia. Because of hydro-
cephalus and marked ventricomegaly,
she required ventriculo-peritoneal shunt
placement. Imaging studies demon-
strated rotoscoliosis. She has had cogni-
tive developmental delay and suffered
from generalized seizures during child-
hood. In her early thirties, she experi-
enced a middle right cerebral artery
stroke. Despite her condition, she
remains high functioning and lives in
an assisted care facility. No other family
members are affected by similar medical
conditions, and no cause has been
attributed to her findings.
In the past year, the patient became
bothered by growths on her forehead and
presented to our clinic. On examination,
frontal bossing was observed, as well as
a yellow-hued papillomatous plaque on
the paramidline forehead that had been
present since birth (Figure 1a). Several
pedunculated papules were noted within
the lesion. No other significant cuta-
neous findings were appreciated.
As per patient request, the lesion was
excised and a portion of the excision
specimen was collected with her written
informed consent. Our study com-
plied with the Declaration of Helsinki
Principles and was approved by the
Stanford Institutional Review Board. His-
tological evaluation confirmed features
of nevus sebaceus with no secondary
neoplasms (Figure 1b). Accordingly, in
light of the extensive neurological and
skeletal involvement, a diagnosis of
Schimmelpenning/nevus sebaceus syn-
drome was made. In efforts to determine
an underlying genetic mutation, four
additional, independent nevus sebaceus
samples were collected from elective
excisions along with adjacent normal
skin controls. The five samples were
subjected to exome sequencing and
analyzed for mutations using Seqgene
(Deng, 2011) and DNAnexus (http://
www.dnanexus.com) as described in
the Supplementary Material online.
Analysis of recurrent lesion-specific
variants identified an HRAS point muta-
tion (c.37G4C, p.Gly13Arg) in the
index case and in two of four isolated
nevus sebaceus samples, with a variant
allele frequency ranging from 17 to
43%. Sanger sequencing confirmed the
HRAS mutation in all five lesional sam-
ples and its absence in all matched
controls (Figure 2a). Examination of the
two HRAS mutation–negative exomes
showed low sequence coverage (o20
reads) at the mutation site, which may
account for the false-negative calls.
Lesions arising along Blaschko’s
lines are hypothesized to stem from a
mosaic mutation affecting a specific cell
lineage during development. To evalu-
ate whether the candidate mutation
fits this criterion, we used laser capture
microdissection to isolate DNA from the
lesional epidermis and dermis from the
index case and one of the sporadic
nevus sebaceus samples. In both cases,
the mutation was limited to the epi-
dermis, supporting the hypothesis of an
acquired mutation affecting ectodermal
precursors (Figure 2b). Both alleles were
represented in approximately equal
intensities, indicating that the mutation
is likely heterozygous.
We next performed targeted Sanger
sequencing on a validation set of 31
independent nevus sebaceus samples
from archived tissues, and identified
the HRAS p.Gly13Arg mutation in
24/31 samples and p.Gly12Asp in one
sample. The remaining mutation-negative
cases were evaluated for KRAS and NRAS
hotspot mutations, identifying two sam-
ples carrying KRAS p.Gly12Asp muta-
tions. Six validation samples had
patient-matched normal skin tissue avail-
able, and the corresponding RAS muta-
tions were absent in all six control
samples. In total, 32 of 36 samples
(89%) demonstrated HRAS or KRAS
mutations, confirming a strong correla-
tion between activating RAS mutations
and nevus sebaceus (Figure 2c). We
suspect that the remaining negative cases
may be due to genetic heterogeneity, or
due to a low mutant allele frequency se-
condary to admixture with normal tissue.
RAS promotes cell growth through
activation of multiple pathways, a main
pathway being the mitogen-activated
protein kinase (MAPK) signal-transduc-
tion pathway. Activating mutations in
this gene family have well-established
links to cancer (Schubbert et al., 2007).
Germline activating HRAS mutations
cause Costello syndrome, which features
predisposition to neoplasia and develop-
ment of cutaneous papillomas (Gripp and
Lin, 2012). Taken together, the known
biological features of activated RAS genes
are consistent with the hamartomatous
a b
Figure 1. Clinical and histological features of a patient with nevus sebaceus syndrome. (a) A yellow-hued,
papillomatous, oblong plaque on the paramidline forehead of the index patient. (b) Hematoxylin and
eosin–stained section (original magnification  40) of a pedunculated papule from the patient’s lesion
showing epidermal acanthosis, papillomatosis, the absence of hair follicles, and ectopic sebaceous glands
opening directly to the epidermal surface. Bar¼ 100mm.
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overgrowth and elevated neoplasia risk
observed in nevus sebaceus.
To evaluate RAS-MAPK signaling, we
performed phosphorylated ERK (pERK)
staining on a set of nevi with confirmed
HRAS mutations. Immunohistochemis-
try revealed increased pERK staining in
lesional versus normal epidermis, con-
sistent with RAS-MAPK hyperactivation
(Figure 2d). In one sample, a squamous
cell carcinoma was identified arising
from nevus sebaceus, highlighted by
elevated p16 staining (Hodges and
Smoller, 2002). The pattern of neopla-
sia arising from a background of upregu-
lated pERK supports the hypothesis that
RAS-MAPK hyperactivation may predi-
spose toward the development of secon-
dary neoplasms in nevus sebaceus.
Basal cell carcinomas were once
thought to arise commonly from nevus
sebaceus, but others have subsequently
contended that the majority of these
tumors are actually trichoblastomas
(Cribier et al., 2000). Our data provide
genetic support for the latter opinion, as
most basal cell carcinomas arise from
Hedgehog pathway dysregulation and
lack RAS mutations (Reifenberger et al.,
2005). Our findings also raise the possi-
bility that tumors arising from nevus
sebaceus, such as syringocystadenoma
papilliferum and trichoblastomas, may
be associated with RAS mutations as well.
Using targeted sequencing and SNaP-
shot assays, Groesser et al. (2012) and
Hafner et al. (2012) have recently pro-
filed oncogenic hotspot mutations in
epidermal and sebaceus nevi. Together
with the results presented here and by
others in this issue (Levinsohn et al.,
2013), the cumulative data demonstrate
that keratinocytic epidermal nevi and
sebaceus nevi are both associated with
activating HRAS p.Gly13Arg and KRAS
p.Gly12Asp mutations, supporting the
belief held by some clinicians that they










































Figure 2. Activating mosaic RAS mutations in nevus sebaceus. (a) Genomic localization of HRAS to the short arm of chromosome 11 and schematic of its gene
structure. A prominent mutational hotspot in coding exon 1 (codons 12–13) is marked with an asterisk. Sanger sequencing confirms a c.37 G4C, p.Gly13Arg
mutation specific to lesional tissue. (b) Laser capture microdissection of the epidermis and dermis of nevus sebaceus demonstrates the presence of the HRAS
mutation exclusively in the epidermis. (c) Summary of RAS mutations identified in nevus sebaceus. (d) The activated RAS/mitogen-activated protein kinase (MAPK)
pathway in nevus sebaceus. Upper row: nevus sebaceus transitioning into normal skin. Immunohistochemical staining for phosphorylated ERK (pERK), a
downstream effector of the RAS pathway, is increased in nevus sebaceus compared with adjacent normal skin. Staining for p16 is homogenously negative. Lower
row: an early focus of squamous cell carcinoma (SCC) arising within a nevus sebaceus. This area is characterized by stronger pERK signal and distinct p16
enrichment. All original magnifications are at 40. Bar¼ 100mm. H&E, hematoxylin and eosin.
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(Sybert, 2010). We postulate that the
phenotypic difference between these
nevi may be related to the extent of the
mutation, as well as body site–specific
embryological patterns and environment.
The knowledge of the genetic basis of
nevus sebaceus and its associated syn-
drome represents a further step toward
understanding genotype–phenotype cor-
relations arising from genetic mosaicism.
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TO THE EDITOR
Epidermal genetic mosaicism is evident
as stripes of affected skin that typically
appear in S- or V-shaped whorled,
streaked, and linear patterns called lines
of Blaschko (Blaschko, 1901). These
patterns represent dorsoventral migratory
pathways of neuroectoderm during em-
bryogenesis (Moss et al., 1993). Mosaic
lesions result from somatic mutation
during development, with timing of
such events determining the extent and
distribution of skin involvement. Epidermal
nevi (EN) are common cutaneous
mosaic disorders seen in 0.1–0.3% of
births, and fall into two classes: kera-
tinocytic epidermal nevi (KEN) and
organoid epidermal nevi, which includes
nevus sebaceus (NS) and follicular
nevi (Solomon and Esterly, 1975). NS
comprises approximately half of EN,
and typically appears on the scalp as a
yellowish–orange linear plaque with
hyperkeratosis, acanthosis, a markedly
increased number of sebaceous lobules,
and abortive hair follicles with resulting
alopecia (Figure 1a–d). In contrast to
KEN, in which neoplasia is rare, tumors
develop in nearly 14% of all NS cases,
and in more than 23% of affected
adults (Cribier et al., 2000), suggest-
ing that the mutation(s) causing NS
also increase the risk of tumorigenesis
(Figure 1e–g).
Recently, somatic mosaicism has
been identified in KEN using SNaPshot
assays to identify mutations in mitogen-
activated protein kinase (MAPK) pathway
genes including FGFR3, HRAS, KRAS,
NRAS, and PIK3CA. Activating Ras
mutations, including HRAS p.Gly13Arg
and KRAS p.Gly12Asp, were most com-
mon and accounted for 39% of KEN,
with HRAS mutations predominating
(Hafner et al., 2012). Similar appro-
aches have been used in NS, identi-
fying HRAS p.Gly13Arg in 91% of
lesions and KRAS p.Gly12Asp in 5%
of lesions (Groesser et al., 2012). We
present an independent, complemen-
tary approach to genetic pathogenesis
in NS, in which we used whole-exome
sequencing to characterize the spectrum
of de novo coding mutations present
within NS lesions.
See related commentary on pg 597
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